For example, erythropoietin for chemotherapy‐induced anaemia modestly improved QOL and reduced transfusion needs, but it increases costs substantially (£1829.77 per patient), and a lack of evidence on survival benefits limits its cost‐effectiveness assessment. This evidence concerns the gene EPO and anemia.